Search

Meeting Coverage:

Aspen Retinal Detachment Society

ARDS: 2019

Vitreoretinal Surgery: When You Do What Others Won't

Timothy G. Murray, MD, MBA

Show Description +

Timothy G. Murray, MD, MBA, discusses the benefits of taking on complex cases. Doing so, Dr. Murray argues, encourages referrals of more difficult cases, which offers an opportunity to improve on existing therapies. Dr. Murray uses his experience in ocular oncology to illustrate his point.

Posted: 3/06/2019

Up Next

FOUNDERS LECTURE: Gene Therapy for Neovascular AMD 2019: Pitfalls and Promise

FOUNDERS LECTURE: Gene Therapy for Neovascular AMD 2019: Pitfalls and Promise

Allen C. Ho, MD, Timothy G. Murray, MD, MBA

Anti-VEGF Treatment for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions

Anti-VEGF Treatment for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions

Mark W. Johnson, MD, Timothy G. Murray, MD, MBA

New Therapies in Wet AMD

New Therapies in Wet AMD

Peter K. Kaiser, MD, Timothy G. Murray, MD, MBA

ILM Peeling in Macular Hole Surgery: When and How

ILM Peeling in Macular Hole Surgery: When and How

David HW Steel, MBBS, FRCOphth, Timothy G. Murray, MD, MBA

TAYLOR SMITH AND VICTOR CURTIN LECTURE: The Essence of Diagnostic Ultrasonography

TAYLOR SMITH AND VICTOR CURTIN LECTURE: The Essence of Diagnostic Ultrasonography

Timothy G. Murray, MD, MBA, Yale L. Fisher, MD

Can We Modify the Natural History of Intermediate AMD?

Can We Modify the Natural History of Intermediate AMD?

Hugo Quiroz-Mercado, MD

Endophthalmitis: Clinical Cases and Management Strategies

Endophthalmitis: Clinical Cases and Management Strategies

Harry W. Flynn Jr, MD, Timothy G. Murray, MD, MBA

Back to All Videos

Vitreoretinal Surgery: When You Do What Others Won't

Timothy G. Murray, MD, MBA

Timothy G. Murray, MD, MBA, discusses the benefits of taking on complex cases. Doing so, Dr. Murray argues, encourages referrals of more difficult cases, which offers an opportunity to improve on existing therapies. Dr. Murray uses his experience in ocular oncology to illustrate his point.

Posted: 3/06/2019

Please log in to leave a comment.

More From ARDS: 2019 Coverage

Can We Modify the Natural History of Intermediate AMD?

Can We Modify the Natural History of Intermediate AMD?

Hugo Quiroz-Mercado, MD

Endophthalmitis: Clinical Cases and Management Strategies

Endophthalmitis: Clinical Cases and Management Strategies

Harry W. Flynn Jr, MD, Timothy G. Murray, MD, MBA

FOUNDERS LECTURE: Gene Therapy for Neovascular AMD 2019: Pitfalls and Promise

FOUNDERS LECTURE: Gene Therapy for Neovascular AMD 2019: Pitfalls and Promise

Allen C. Ho, MD, Timothy G. Murray, MD, MBA

Anti-VEGF Treatment for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions

Anti-VEGF Treatment for Diabetic Retinopathy: Consequences of Inadvertent Treatment Interruptions

Mark W. Johnson, MD, Timothy G. Murray, MD, MBA

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ARDS: 2019.